Home

Jeff Goater

CIK 1656435 · Chief Executive Officer · last filed 2023-09-08

Jeff Goater is a Chief Executive Officer who has filed 19 SEC Form 4 insider transactions across 4 companies since 2016. The most recent filing, for SURF, was dated Sep 8, 2023. Across all open-market trades the lifetime net is −$2.8M, making them a net seller over the disclosed history. 4 SEC filings were submitted jointly with VACCINEX, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

4

Total Filings

19

Lifetime Open-Market Net

-$2.80M

Filer Profile

Reported Address
C/O SURFACE ONCOLOGY, INC.
50 HAMPSHIRE STREET, 8TH FLOOR
CAMBRIDGE, MA 02139
Related Filers
VACCINEX, INC. — 4 joint filings, latest 2021-05-12
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Surface Oncology, Inc. (SURF) Delisted Director 0 $1.07 $0 -$2.80M 11 2023-09-08
LogicBio Therapeutics, Inc. (LOGC) Delisted Director — $7.06 — $0 4 2022-11-17
VACCINEX, INC. (VCNX) Delisted Director 1 $1.00 $1 $0 3 2021-05-12
VYGR Chief Financial Officer — $3.19 — $0 1 2016-02-02

Recent Filings

19 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-09-08 Surface Oncology, Inc. (SURF) Delisted Disp (D) −129,222 $0 EDGAR
2022-11-17 LogicBio Therapeutics, Inc. (LOGC) Delisted Disp (D) — $0 EDGAR
2022-06-21 LogicBio Therapeutics, Inc. (LOGC) Delisted Grant (A) — $0 EDGAR
2022-06-10 Surface Oncology, Inc. (SURF) Delisted Grant (A) — $0 EDGAR
2022-01-14 Surface Oncology, Inc. (SURF) Delisted Sell (S) −127,778 -$779.4K EDGAR
2021-06-14 LogicBio Therapeutics, Inc. (LOGC) Delisted Grant (A) — $0 EDGAR
2021-06-11 Surface Oncology, Inc. (SURF) Delisted Mixed −5,000 -$900.5K EDGAR
2021-05-12 VACCINEX, INC. (VCNX) Delisted Grant (A) — $0 EDGAR
2021-04-02 Surface Oncology, Inc. (SURF) Delisted Grant (A) — $0 EDGAR
2021-02-09 Surface Oncology, Inc. (SURF) Delisted Mixed — -$23.3K EDGAR
Showing 1–10 of 19
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.